NICE guidance on type-2 diabetes

Draft NICE guidelines on type-2 diabetes have backed second-line use of DPP-4 inhibitors and glitazones in some patients.

The recommendations cover DPP-4 inhibitors (sitagliptin and vildagliptin), glitazones (pioglitazone and rosiglitazone) and exenatide, as well as when to start insulin therapy.

Metformin and a sulphonylurea remain preferred first- and second-line agents, but for patients not suitable for this treatment and who are uncontrolled on one of them, a DPP-4 inhibitor or a glitazone is recommended as an add-on therapy.

Exenatide can be added to metformin and a sulphonylurea for obese patients and those unsuitable for insulin therapy.

tom.moberly@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Most children could be removed from shielded patient list, deputy CMO suggests

Most children could be removed from shielded patient list, deputy CMO suggests

Most children could be removed from the shielded patient list in a future wave of...

GPs can provide some care for shielded patients in clinical settings, NHS England confirms

GPs can provide some care for shielded patients in clinical settings, NHS England confirms

GPs can provide care to shielded patients in 'infection-controlled clinical settings'...

How digital assistants can help patients manage their health and wellbeing

How digital assistants can help patients manage their health and wellbeing

A project in Staffordshire has shown how practices can make use of digital technology...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

Fair death-in-service deal for locums vital before second COVID-19 wave, warns BMA

Fair death-in-service deal for locums vital before second COVID-19 wave, warns BMA

The government must do ‘the right thing’ and secure adequate death-in-service benefits...

GP workload fears over antibody testing rollout for 'no clinical benefit'

GP workload fears over antibody testing rollout for 'no clinical benefit'

GP practices are being contacted by patients asking for antibody tests as the government...